The FDA extended its review of Exelixis' cancer drug zanzalintinib by three months without revealing any new clinical failures or safety concerns. This delay reduces the drug's present value by about 2.35%, which is less than the initial market loss. Exelixis' other drug, CABOMETYX, continues to grow, and the company's 2026 revenue guidance does not include zanzalintinib sales. The stock trades at a reasonable valuation, and the analyst maintains a Buy rating with a $68 price target.
Bitcoin is trading around $77,327 with minor daily gains but a weekly drop over 3%, facing resistance between $77,100 and $80,200 where long-term holders have sold significant amounts. CryptoQuant highlights $81,700 as a key level to confirm a new bu...
Spot Bitcoin ETFs experienced $462.7 million in net outflows from September 8 to 11, reversing nearly half of the previous week's inflows. This shift coincides with markets pricing in an 87% chance of a 25-basis-point rate hike at the upcoming Septem...
Visa reported better-than-expected Q3 results, with net revenue up 14%, earnings per share rising 11%, and free cash flow reaching about $6.14 billion. The company is expanding its value-added services and forming strategic partnerships to diversify ...
Tom Lee, co-founder of Fundstrat, states that Ethereum is becoming the key settlement layer for Wall Street and artificial intelligence (AI) applications. Despite a broader crypto market pullback, Ethereum has outperformed most major cryptocurrencies...
Mondelez International has opened a $22 million chocolate crumb production facility in Shah Alam, Malaysia, reducing supply-chain lead time by at least two months for a key Cadbury ingredient. This local production replaces imports from Australia and...
